What sector does Catalyst Pharmaceuticals Partners, Inc. belong to?

Catalyst Pharmaceuticals Partners, Inc. operates in the Health Care sector, specifically the Biotechnology industry, and is listed on the US markets.

What is the current share price of CPRX?

As of the latest available quote, CPRX traded at $31.49. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of CPRX?

Catalyst Pharmaceuticals Partners, Inc. has a price-to-earnings (P/E) ratio of about 18.74. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of CPRX?

The market capitalisation of Catalyst Pharmaceuticals Partners, Inc. is approximately $4.02B.

Is Catalyst Pharmaceuticals Partners, Inc. profitable?

For its latest reported financial year, Catalyst Pharmaceuticals Partners, Inc. recorded a net profit margin of about 36.39%.

What is the return on equity (ROE) of CPRX?

Catalyst Pharmaceuticals Partners, Inc. has a return on equity (ROE) of about 21.16%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of CPRX?

Over the past 52 weeks, CPRX has traded between a low of $19.05 and a high of $32.56.

Catalyst Pharmaceuticals Partners, Inc.

CPRX US Health Care Biotechnology

S&P 600

$31.49

Delayed · cached 15 min

Fair value analysis

CPRX

Catalyst Pharmaceuticals Partners, Inc.

$31.49

Close used for this calculation

$34.14Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

74/100

Profitability25/25

Returns13/25

Balance Sheet21/25

Efficiency15/25

Growth14/25

Strong

Quality radar

Consensus fair value

$34.14

Near FV

▲ +8.4% against the close used

Model range $24.77 – $50.40

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$24.77Fair value$34.14Bull$50.40

FairClose

52-week traded range

52W low $19.1352W high $31.50

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Catalyst Pharmaceuticals Partners, Inc. closed at $31.49, 7.8% below the consensus fair value of $34.14 drawn from 7 valuation models.

Financial DNA score 74/100 — Strong. P/E of 18.7x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$32.46

+3.1%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

P/E Fair Value

$33.60

+6.7%

EPS × 20x (sector P/E)

EPS=1.68, Sector P/E=20x

Peter Lynch (PEG)

$50.40

+60.1%

EPS × Growth% (PEG = 1 is fair)

EPS=1.68, g=30%

EV/EBITDA

$36.42

+15.7%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=258.15M

Book Value (P/B)

$30.21

-4.1%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=7.97, ROE=21.2%, g=6%, r=10%

Reverse DCF

$31.49

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 6.3% | Historical: 33.3%

Margin of Safety

$24.77

-21.3%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=33.03, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer